Ischemic Heart Disease: What to Do When Beta-Blockers Fail to Control Angina

In ischemic heart disease, first-line anti-angina therapy does not always achieve adequate symptom control. When angina persists despite initial treatment, a structured, evidence-based second-line approach is indicated.

First-Line Therapy — Goals Not Met

The previous line of treatment included beta-blockers as the primary anti-angina agent, alongside aspirin and statins. The goals — reducing angina frequency and symptoms, and raising the threshold at which angina occurs — were not sufficiently reached, making escalation necessary.

Second-Line Approach (Partial)

The next step involves adding a further class of anti-angina agent to the existing regimen — the complete selection and clinical decision logic are detailed in the structured protocol.

Clinical Targets

Reduction in angina symptoms and episodes; improved exercise capacity.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1093/eurheartj/suaa060

Calcium channel blockers are currently recommended in angina as second-line therapy after BBs, along with nitrates.

Guidelines recommend the use of long-acting nitrates as second-line agents after BBs or when BBs are contraindicated.

Instead, long-term preparations such as isosorbide mononitrate or isosorbide dinitrate are frequently used for angina prophylaxis.

In terms of anti-angina efficacy, numerous studies over the last few decades have clearly identified calcium channel blockers (dihydropyridines and others) as an effective therapy for reducing angina symptoms.

Although previous studies have clearly shown the role of nitrates in improving exercise capacity and reducing angina episodes, high-quality studies that examine the impact of nitroglycerine on ‘hard’ clinical endpoints are lacking.

View source ↗